Sub-toxic cisplatin mediates anoikis resistance through hydrogen peroxide-induced caveolin-1 up-regulation in non-small cell lung cancer cells

Anticancer Research

Volumn 32, Issue 5, 2012, Pages 1659-1670

  Songserm, Thitiporn ^a   Pongrakhananon, Varisa ^a   Chanvorachote, Pithi ^a  

^a CHULALONGKORN UNIVERSITY   (Thailand)

Author keywords

Anoikis; Caveolin 1; Cisplatin; H460; Hydrogen peroxide; Lung cancer cells

Indexed keywords

CAVEOLIN 1; CISPLATIN; HYDROGEN PEROXIDE; REACTIVE OXYGEN METABOLITE; SUPEROXIDE;

ANOIKIS; ARTICLE; ATTENUATION; CARCINOMA CELL; CONTROLLED STUDY; DRUG EXPOSURE; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; LUNG NON SMALL CELL CANCER; MOLECULAR PROBE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECEPTOR UPREGULATION; WESTERN BLOTTING;

ANOIKIS; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; CAVEOLIN 1; CELL LINE, TUMOR; CISPLATIN; DRUG RESISTANCE, NEOPLASM; HUMANS; HYDROGEN PEROXIDE; LUNG NEOPLASMS; REACTIVE OXYGEN SPECIES; UP-REGULATION;

EID: 84861510336     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (49)

1. Sleijfer DT, Meijer S and Mulder NH: Cisplatin: a review of clinical applications and renal toxicity. Pharm World Sci 7: 237- 244, 1985.
2. Loehrer PJ and Einhorn LH: Cisplatin. Ann Intern Med 100: 704-713, 1984. (Pubitemid 14143951)
3. Ozols RF: Ovarian cancer, Part II: treatment. Curr Prob Cancer 16: 63-126, 1992.
4. Wong E and Giandomenico CM: Current status of platinum-based antitumor drugs. Chem Rev 99: 2451-2466, 1999.
5. Gerl A, Clemm C, Schmeller N, Hentrich M, Lamerz R and Wilmanns W: Late relapse of germ cell tumors after cisplatin-based chemotherapy. Ann Oncol 8: 41-47, 1997. (Pubitemid 27112801)
6. Cognetti F, Ruggeri EM, Felici A, Gallucci M, Muto G, Pollera CF, Massidda B, Rubagotti A, Giannarelli D and Boccardo, F: Adjuvant chemotherapy with cisplatin and gemcitabine versus chemotherapy at relapse in patients with muscle-invasive bladder cancer submitted to radical cystectomy: an Italian, multicenter, randomized phase III trial. Ann Oncol 23: 695-700, 2012
7. Parez RP: Clinical oncology update: cellular and molecular determinants of cisplatin Resistance. Eur J Cancer 34: 1535- 1542, 1998.
8. Kelland L: The resurgence of platinum-based cancer chemotherapy. Nat Rev Cancer 7: 573-584, 2007.
9. Li HL, Xie SM, Zhang L, Cai CJ, Wang W, Huang J, Wang DY, Wen DP, Deng QH, Zhong NS and He JX: Establishment and characterization of a new drug surviving cell line Am1010, derived directly from muscle metastases of a human lung adenocarcinoma patient with multi-drug-resistance to cisplatin, taxol, and gefitinib. Acta Pharmacol Sin 31: 601-608, 2010.
10. Oliver TG, Mercer KL, Sayles LC, Burke JR, Mendus D, Lovejoy KS, Cheng MH, Subramanian A, Mu D, Powers S, Crowley D, Bronson RT, Whittaker CA, Bhutkar A, Lippard SJ, Golub T, Thomale J, Jacks T and Sweet-Cordero EA: Chronic cisplatin treatment promotes enhanced damage repair and tumor progression in a mouse model of lung cancer. Genes Dev 24: 837-852, 2010.
11. Baselga J, Trigo JM, Bourhis J, Tortochaux J, Cortés-Funes H, Hitt R, Gascón P, Amellal N, Harstrick A and Eckardt A: Phase II multicenter study of the antiepidermal growth factor receptor monoclonal antibody cetuximab in combination with platinum-based chemotherapy in patients with platinum-refractory metastatic and/or recurrent squamous cell carcinoma of the head and neck . J Clin Oncol 24: 5568-5577, 2005.
12. Godwin AK, Meister A, O'Dwyer PJ, Huang CS, Hamilton TC and Anderson ME: High resistance to cisplatin in human ovarian cancer cell lines is associated with marked increase of glutathione synthesis. Proc Natl Acad Sci USA 1: 3070-3074, 1922.
13. Kelly SL, Basu A, Teicher BA, Hacker MP, Hamer DH and Lazo JS: Overexpression of metallothionein confers resistance to anticancer drugs. Science 241: 1813-1815, 1998.
14. Hall MD, Okabe M, Shen DW, Liang XJ and Gottesman MM: The role of cellular accumulation in determining sensitivity to platinum-based chemotherapy. Annu Rev Pharmacol Toxicol 48: 495-535, 2008. (Pubitemid 351738162)
15. Peklak-Scott C, Smitherman PK, Townsend AJ and Morrow CS: Role of glutathione S-transferase P1-1 in the cellular detoxification of cisplatin. Mol Cancer Ther 7: 3247-3255, 2008.
16. Frisch SM and Francis H: Disruption of epithelial cell matrix interactions induces apoptosis. J Cell Biol 124: 619-626, 1994. (Pubitemid 24064472)
17. Frisch SM and Screaton RA: Anoikis mechanisms. Curr Opin Cell Biol 13: 555-562, 2001. (Pubitemid 32817013)
18. Grossmann J: Molecular mechanisms of detachment induced apoptosis-anoikis. Apoptosis 7: 247-260, 2002.
19. Mehlen P and Puisieux A: Metastasis: a question of life or death. Nat Rev Cancer 6: 449-458, 2006.
20. Rungtabnapa P, Nimmannit U, Halim H, Rojanasakul Y and Chanvorachote P: Hydrogen peroxide inhibits non-small cell lung cancer cell anoikis through the inhibition of caveolin degradation. Am J Physiol Cell Physiol 300: C235-245, 2011.
21. Terence MW and Michael PL: Caveolin-1 in oncogenic transformation, cancer, and metastasis. Am J Physiol Cell Physiol 288: 494-506, 2005.
22. Di Vizio D, Sotgia F, Williams TM, Hassan GS, Capozza F, Frank PG, Pestell RG, Loda M, Freeman MR and Lisanti MP: Caveolin-1 is required for the upregulation of fatty acid synthase (FASN), a tumor promoter, during prostate cancer progression. Cancer Biol Ther 6: 1263-1268, 2007. (Pubitemid 351590381)
23. Nasu Y, Timme TL and Yang G: Suppression of caveolin expression induces androgen sensitivity in metastatic androgen-insensitive mouse prostate cancer cells. Nat Med 4: 1062-1064, 1988.
24. Yang G, Truong LD, Timme TL, Ren C, Wheeler TM, Park SH, Nasu Y, Bangma CH, Kattan MW, Scardino PT and Thompson TC: Elevated expression of caveolin is associated with prostate and breast cancer. Clin Cancer Res 4: 1873-1880, 1988.
25. Thompson TC: Metastasis-related genes in prostate cancer: the role of caveolin-1. Cancer Metastasis Rev 17: 439-442, 1999.
26. Ho CC, Huang PH, Huang HY, Chen YH, Yang PC and Hsu SM: Up-regulated caveolin-1 accentuates the metastasis capability of lung adenocarcinoma by inducing filopodia formation. Am J Pathol 161: 1647-1656, 2002.
27. Suzuoki M, Miyamoto M and Kato K: Impact of caveolin-1 expression on prognosis of pancreatic ductal adenocarcinoma. Br J Cancer 87: 1140-1144, 2002. (Pubitemid 35418110)
28. Sies H: Oxidative stress: oxidants and antioxidants. Exp Physiol 82: 291-295, 1997.
29. Polytarchou C, Hatziapostolou M and Papadimitriou E: Hydrogen peroxide stimulates proliferation and migration of human prostate cancer cells through activation of activator protein-1 and up-regulation of the heparin affin regulatory peptide gene. J Biol Chem 280: 40428-40435, 2005. (Pubitemid 41780529)
30. Halliwell B: Biochemistry of oxidative stress. Biochem Soc Trans 35: 1147-1150, 2007.
31. Klaunig JE, Kamendulis LM and Hocevar BA: Oxidative stress and oxidative damage in carcinogenesis. Toxicol Pathol 38: 96- 109, 2010.
32. Brown NS and Bicknell R: Hypoxia and oxidative stress in breast cancer: oxidative stress its effects on the growth, metastatic potential and response to therapy of breast cancer. Breast Cancer Res 3: 323-327, 2001. (Pubitemid 32851163)
33. Ishikawa K, Takenaga K, Akimoto M, Koshikawa N, Yamaguchi A, Imanishi H, Nakada K, Honma Y and Hayashi J: ROS-generating mitochondrial DNA mutations can regulate tumor cell metastasis. Science 320: 661-664, 2008. (Pubitemid 351928347)
34. Nishikawa M, Hashida M and Takakura Y: Catalase delivery for inhibiting ROS-mediated tissue injury and tumor metastasis. Adv Drug Deliv Rev 61: 319-326, 2009.
35. Miyajima A, Nakashima J, Yoshioka K, Tachibana M, Tazaki H and Mural M: Role of reactive oxygen species in cis-dichlorodiammineplatinum- induced cytotoxicity on bladder cancer cells. Br J Cancer 76: 206-210, 1997. (Pubitemid 27279660)
36. Schweyer S, Soruri A, Heintze A, Radzun HJ and Fayyazi A: The role of reactive oxygen species in cisplatin-induced apoptosis in human malignant testicular germ cell lines. Int J Oncol 25: 1671-1676, 2004.
37. Seve P and Dumontet C: Chemoresistance in non-small cell lung cancer. Curr Med Chem Anticancer Agents 5: 73-88, 2005. (Pubitemid 40081296)
38. Berndtsson M, Hagg M, Panaretakis T, Havelka AM, Shoshan MC and Linder S: Acute apoptosis by cisplatin requires induction of reactive oxygen species but is not associated with damage to nuclear DNA. Int J Cancer 120: 175-180, 2006. (Pubitemid 44901933)
39. Nishio K, Nakamura T, Koh Y, Suzuki T, Fukumoto H and Saijo N: Drug resistance in lung cancer. Curr Opin Oncol 11: 109-115, 1999. (Pubitemid 29151469)
40. Hoffman PC, Mauer AM and Vokes EE: Lung cancer. Lancet 355: 479-485, 2000. (Pubitemid 30085163)
41. Socinski MA: Cytotoxic chemotherapy in advanced nonsmall cell lung cancer: a review of standard treatment paradigms. Clin Cancer Res 10: 4210s-4214s, 2004. (Pubitemid 38812448)
42. Wang L, Chanvorachote P, Toledo D, Stehlik C, Mercer RR, Castranova V and Rojanasakul Y: Peroxide is a key mediator of BCL2 down-regulation and apoptosis induction by cisplatin in human lung cancer cells. Mol Pharmacol 73: 119-127, 2007.
43. Chanvorachote P, Pongrakhananon V, Wannachaiyasit S, Luanpitpong S, Rojanasakul Y and Nimmannit U: Curcumin sensitized lung cancer cells to cisplatin-induced apoptosis through superoxide anion induction and Bcl-1 degradation. Cancer Invest 27: 624-635, 2009.
44. Pongjit K and Chanvorachote P: Caveolin-1 sensitizes cisplatin-induced lung cancer cell apoptosis via superoxide anion-dependent mechanism. Mol Cell Biochem 358: 365-373, 2011.
45. Lavie Y and Liscovitch M: A role for caveolae in multidrug resistance of cancer cells. Mol Biol Cell 8: 207, 1997.
46. Lavie Y, Fiucci G and Liscovitch M: Up-regulation of caveolae and caveolar constituents in multidrug-resistant cancer cells. J Biol Chem 273: 32380-32383, 1998. (Pubitemid 28557607)
47. Shatz M and Liscovitch M: Caveolin-1 and cancer multidrug resistance: Coordinate regulation of pro-survival proteins? Leuk Res 28: 907-908, 2004. (Pubitemid 38953644)
48. Choi BK, Choi CH, Oh HL and Kim YK: Role of ERK activation in cisplatin-induced apoptosis in A172 human glioma cells. Neurotoxicol 25: 915-924, 2004. (Pubitemid 39335584)
49. Jiang M, Wei Q, Pabla N, Dong G, Wang CY, Yang T, Smith SB and Dong Z: Effects of hydroxyl radical scavenging on cisplatin-induced p53 activation, tubular cell apoptosis and nephrotoxicity. Biochem Pharmacol 73: 1499-1510, 2007.